HK Stock Market Move | HAIZHI TECH GP(02706) rose over 7% after entering into a strategic cooperation framework agreement with Jointown Pharmaceutical Group to help drive the digital and intelligent transformation of the pharmaceutical distribution industry.

HAIZHI TECH GP(02706) rose over 7%, up 4.55% as of press time, at HK$28.5, with a turnover of HK$26.3646 million. On the news front, HAIZHI TECH GP announced that the Company recently entered into a strategic cooperation framework agreement (the "Strategic Cooperation Framework Agreement") with Jointown Pharmaceutical Group Co., Ltd. (Jointown Pharmaceutical Group). Pursuant to the Strategic Cooperation Framework Agreement, the Company and Jointown Pharmaceutical Group will carry out strategic cooperation around the digital and intelligent transformation of the pharmaceutical distribution industry, including but not limited to using the Atlas graph solution and Atlas agent as carriers, relying on multi-modal database and ontology (Ontology) technology, to build a two-tier empowerment architecture of "data and business semantic foundationagent application," providing intelligent decision support for Jointown Pharmaceutical Group's supply chain business. Jointown Pharmaceutical Group is a leading domestic pharmaceutical distribution industry group, whose A-shares are listed on the Shanghai Stock Exchange (stock code: 600998.SH). Jointown Pharmaceutical Group has a nationwide distribution, logistics and terminal service network, and has deep business accumulation across the entire distribution chain, including procurement, inventory, warehousing, transportation, orders, quality management, finance, and customer operations. The board of directors of the Company believes that, leveraging the respective technological advantages, industry experience and market resources of both parties, the strategic cooperation proposed under the Strategic Cooperation Framework Agreement will achieve resource complementarity and collaborative development, and help drive the digital and intelligent transformation (i.e., AI-driven upgrade) of the pharmaceutical distribution industry.